NCT05184218View on ClinicalTrials.gov

Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19

PHASE1TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

May 6, 2022

Study Completion Date

July 4, 2022

Conditions
Healthy VolunteersCOVID-19
Interventions
DRUG

IGM-6268

Active Comparator

DRUG

Placebo

Placebo Comparator

Trial Locations (1)

9301

Farmovs, Bloemfontein

Sponsors
All Listed Sponsors
lead

IGM Biosciences, Inc.

INDUSTRY